Future-Proofing Early Development with Strategic PICO Planning
A global pharmaceutical company with a diverse pipeline needed to align early clinical planning with future market access requirements—before Phase II. With Target Product Profiles (TPPs) still in development, the team turned to NAVLIN by EVERSANA® to anticipate EU Joint Clinical Assessment (JCA) expectations and build a strategic PICO framework that could evolve with the data.
To stay ahead of shifting HTA requirements and competitive dynamics, the goal was clear: develop a flexible, forward-looking PICO strategy to guide Phase II/III trial design and long-term evidence planning.
In this case study, you’ll learn how NAVLIN by EVERSANA’s PICO planner helped:
- Anticipate HTA-relevant endpoints and comparators across 27 EU countries
- Align trial design with evolving regulatory and payer expectations
- Create a roadmap for updating PICOs as data and market conditions change
Download the full case study to see how NAVLIN by EVERSANA helps teams build smarter, more adaptable development strategies.
Author
Shivani Shah is Senior Consultant at EVERSANA and has around 6 years of experience working as consultant in pharmaceutical and life-science industry. Prior to joining EVERSANA, she has worked at one of the top…
As a Director of Global Market Access and Pricing, Richard leads global consulting engagements within EVERSANA. Richard comes with 13+ year of Life Sciences Consulting and Industry experience. He supported 40+ pharma brands preparing…